65,437 trials
HIV Infections
Primary: Mean Change From Baseline in HIV Ribonucleic Acid (RNA) at Week 24 — -1.86; -1.52; -1.89 log10 c/mL
Parkinson Disease · Parkinson's Disease
Primary: Number of Participants With the Indicated Number of Adverse Events (AEs) and Serious Adverse Events (SAEs) — 365; 109; 213; 106 participants
Psoriasis
Primary: Number of Participants Who Achieve a Greater Than or Equal to 75% Improvement in Psoriasis Area and Severity Index (PASI) Score — 111; 111 Participants
Myopia
Primary: Comfort After Insertion — 9.0 Units on a Scale
Growth Hormone Deficiency · Idiopathic Short Stature
Primary: Percentage of Dyads (Participant and Caregiver or Parent) Reporting no Difference or Easier to Use for New Genotropin Mark VII Injection Pen Compared to Pre-study…
Neoplasms · Prostatic Neoplasms
Primary: Overall Survival — 12.7; 15.1 Months — p=<0.0001
Dental Caries
Primary: ICDAS Severity Value — 17; 22; 278; 273 teeth — p=0.1126
Pulmonary Disease, Chronic Obstructive
Primary: Mean Change From Baseline in Aortic Pulse Wave Velocity (aPWV) at the 12-Week Endpoint — 10.06; 9.87; 9.83; 9.95 meters per second (m/s) — p=0.065
Neisseria Meningitidis · Haemophilus Influenzae Type b
Primary: Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Titers Using Rabbit Complement (rSBA-MenC) Equal to or Above Cut-off Value — 120; 144; 127; 113…
Meningitis · Meningococcal Infection · Neisseria Meningitidis
Primary: Percentage of Participants With Meningococcal Antibody Titers ≥ 8 After Each Vaccination — 59; 36; 65; 83 Percentage of Participants
Scalp Psoriasis
Primary: Number of Participants Who Were a Success or Failure Based on the Global Severity Score (GSS) of Scalp Psoriasis From Baseline to End of Treatment (Week 4 or Week 2 if…
Smoking · Tobacco Use Disorder
Primary: Point Prevalence Smoking Abstinence at 12 Weeks: the Number of Patients Who Refrained From Smoking at 12 Weeks — 27 Participants
Multiple Sclerosis
Primary: The Primary Endpoint is the Proportion of RMS Subjects Rating the RebiSmart™ Autoinjector as 'Easy to Use' or 'Very Easy to Use' for Self-injection in a User Trial…
Breast Cancer · Drug/Agent Toxicity by Tissue/Organ · Endometrial Cancer
Primary: Number of Participants With Palmar-plantar Erythrodysesthesia (PPE) — 2; 3; 3; 3 participants — p=<0.05
Infant Respiratory Distress Syndrome · Respiratory Insufficiency · Apnea of Prematurity
Primary: pCO2 Measurements Post-intervention, as Compared to Pre-intervention Values — 50; 45 mm Hg — p=0.011